Wave Life Sciences — Merger or Acquisition (December 2022)

5 slides from Wave Life Sciences's merger presentation, Dec 13, 2022

Slide 1: Wave and GSK Collaboration
Wave and GSK Collaboration December 13, 2022 Exhibit 99.2
Slide 2: Forward-looking statements
Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, r
Slide 3: Strategic collaboration with GSK to develop RNA therapeutics for genetically defined diseases
Collaboration leverages Wave’s unique stereopure, PN-chemistry containing PRISM™ platform, including editing, splicing, silencing (RNAi and antisense) Strategic collaboration with GSK to develop transformative RNA therapeutics for genetically defined diseases 1$120 million in cash and $50 million eq
Slide 4: Q&A
Q&A
Slide 5: Realizing a brighter future for people affected by genetic diseases
Realizing a brighter future for people affected by genetic diseases For more information: Kate Rausch, Investor Relations InvestorRelations@wavelifesci.com 617.949.4827